Articles tagged with 'Export-TopNews' | Bayer

Holistic approach to improve water use and quality across the entire value chain and contribute to an impactful change / Integration of water stewardship in business and investment decisions / Shaping a water-resilient agriculture system with key con...

Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial ...

European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III ARASENS trial data...

Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PUL...

Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros / EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science / Pharmaceuticals increases sa...

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS trial 

New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various t...

European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (...

Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented...

Biological pheromones present a non-toxic, innovative opportunity for biological crop protection while safeguarding biodiversity and beneficial pollinators / M2i’s patented bio-sourced micro-encapsulation technology means long-lasting pheromone contr...

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with sim...

Strong market uptake of Nubeqa™ and Kerendia™ / Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention  / High-value late-stage development portfolio  / Positive study outcomes from ce...

CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease...

Bayer receives the highest CDP score for its activities and transparency in climate change / This rating confirms the company’s high commitment to sustainability / A record-breaking 18,700 companies disclosed data on environmental impacts, risks, and...

Financial support for the Chernihiv Medical Center of Modern Oncology and the Romodanov Institute of Neurosurgery / The donation goes to UNITED24, the main platform for charitable donations to reconstruct Ukraine  ...

Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / Bayer will apply for a patent term extension for the pat...

Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer H...

Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients  / Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vaso...

Business to continue operations as an independent company called Envu

Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea® (aflibe...

Succeeds Fei-Fei Li, who stepped down at the end of August

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-ris...

Leverkusen, August 18, 2022 – Bayer supports the humanitarian non-profit organization “Fondation suisse de déminage” (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A ...

Following strong second quarter results, Bayer’s Fields of Opportunity Technology Showcase highlights cutting-edge technologies and pipeline solutions expected to propel farmer productivity, sustainability, and company growth / Featured breakthrough ...

Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC) / Today’s approval under the FDA’s Re...

Group sales increase by 9.6 percent (Fx & portfolio adj.) to 12.819 billion euros / EBITDA before special items rises by 30.0 percent to 3.349 billion euros / Crop Science and Consumer Health achieve strong sales and earnings growth / Pharmaceuticals...

Supports ongoing transformation of Bayer’s Pharma business to focus on key areas of future medical innovation / Transaction value of up to 500 million Euro / Closing expected by end of 2022

Establishment of new precision molecular oncology research center to drive development of novel targeted cancer therapies for patients with unmet medical need / Strategic investment of $140M USD to expand presence in leading center of biotech innovat...

AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity / Cloud-hosted platform provides access to AI applications that integrate into standard medical imaging workflow / Market introduction t...

SAN DIEGO - June 23, 2022 - Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorde...